- Home
- NHS vs CRVS Comparison
NHS vs CRVS Comparison
Compare NHS & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NHS
- CRVS
- Stock Information
- Founded
- NHS 2003
- CRVS 2014
- Country
- NHS United States
- CRVS United States
- Employees
- NHS N/A
- CRVS N/A
- Industry
- NHS Trusts Except Educational Religious and Charitable
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- NHS Finance
- CRVS Health Care
- Exchange
- NHS Nasdaq
- CRVS Nasdaq
- Market Cap
- NHS 221.6M
- CRVS 206.5M
- IPO Year
- NHS N/A
- CRVS 2016
- Fundamental
- Price
- NHS $7.70
- CRVS $3.89
- Analyst Decision
- NHS
- CRVS Strong Buy
- Analyst Count
- NHS 0
- CRVS 3
- Target Price
- NHS N/A
- CRVS $16.33
- AVG Volume (30 Days)
- NHS 111.8K
- CRVS 1.6M
- Earning Date
- NHS 01-01-0001
- CRVS 05-08-2025
- Dividend Yield
- NHS 13.44%
- CRVS N/A
- EPS Growth
- NHS N/A
- CRVS N/A
- EPS
- NHS N/A
- CRVS N/A
- Revenue
- NHS N/A
- CRVS N/A
- Revenue This Year
- NHS N/A
- CRVS N/A
- Revenue Next Year
- NHS N/A
- CRVS N/A
- P/E Ratio
- NHS N/A
- CRVS N/A
- Revenue Growth
- NHS N/A
- CRVS N/A
- 52 Week Low
- NHS $6.95
- CRVS $1.75
- 52 Week High
- NHS $9.17
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- NHS 59.96
- CRVS 55.72
- Support Level
- NHS $7.53
- CRVS $3.84
- Resistance Level
- NHS $7.64
- CRVS $4.53
- Average True Range (ATR)
- NHS 0.09
- CRVS 0.27
- MACD
- NHS 0.02
- CRVS 0.09
- Stochastic Oscillator
- NHS 90.74
- CRVS 53.11
About NHS Neuberger Berman High Yield Strategies Fund
Neuberger Berman High Yield Strategies Fund is closed-end management investment company. It seeks to achieve its investment objective by investing, under normal market conditions, a majority of its total assets in high yield debt securities of U.S. and foreign issuers.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).